BSR_14_0066_A2_S94
— · C
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- C
- subtype
- C
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- OXIDATIVE_PHOSPHORYLATION+0.510
- PROTEIN_SECRETION+0.420
- FATTY_ACID_METABOLISM+0.380
- ADIPOGENESIS+0.350
- MTORC1_SIGNALING+0.340
- CHOLESTEROL_HOMEOSTASIS+0.330
- PEROXISOME+0.330
- E2F_TARGETS+0.310
- MYC_TARGETS_V1+0.290
- PI3K_AKT_MTOR_SIGNALING+0.280
Top 10 suppressed
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.610
- ANGIOGENESIS-0.490
- UV_RESPONSE_DN-0.430
- TGF_BETA_SIGNALING-0.390
- IL6_JAK_STAT3_SIGNALING-0.370
- INFLAMMATORY_RESPONSE-0.360
- ALLOGRAFT_REJECTION-0.350
- TNFA_SIGNALING_VIA_NFKB-0.350
- MYOGENESIS-0.340
- APICAL_JUNCTION-0.320
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-A8-A06Z-01A-11R-A00Z-07 | — | B | 0.908 |
| 2 | SRR8518448 | — | C | 0.907 |
| 3 | TCGA-A8-A06Q-01A-11R-A034-07 | — | C | 0.906 |
| 4 | ULC0410T_S45 | — | cohortA4 | 0.901 |
| 5 | dfb9c45f-cb52-4e36-b663-1a9e8c7c0b47 | — | — | 0.892 |
| 6 | fd49c74b-2a85-46cd-aaa0-dbd2f1284947 | — | — | 0.891 |
| 7 | SRR10900021 | — | — | 0.886 |
| 8 | SRR12202421 | — | — | 0.885 |
| 9 | SRR2932846 | — | — | 0.883 |
| 10 | SRR26320065 | — | — | 0.874 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 23 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| OXIDATIVE_PHOSPHORYLATION | 0.510 | Remibrutinib | — uncovered |
| PROTEIN_SECRETION | 0.420 | Remibrutinib | — uncovered |
| FATTY_ACID_METABOLISM | 0.380 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.350 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.340 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.330 | Remibrutinib | — uncovered |
| PEROXISOME | 0.330 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.310 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.290 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.280 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.270 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.260 | Idelalisib | — uncovered |
| GLYCOLYSIS | 0.220 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.220 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.170 | Idelalisib | — uncovered |
| MYC_TARGETS_V2 | 0.170 | Idelalisib | — uncovered |
| UV_RESPONSE_UP | 0.150 | Idelalisib | — uncovered |
| ANDROGEN_RESPONSE | 0.140 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.130 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.100 | Inavolisib | — uncovered |